{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-024898","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.025783+00:00","generated_at":"2026-06-06T00:10:11.080070+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SELLAS receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure","bullets":["Nasdaq notified SELLAS on Feb 14, 2024 that common stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.","No immediate impact on listing or trading; stock continues trading under symbol SLS.","Company has 180 calendar days, until Aug 12, 2024, to regain compliance by closing bid price >=$1.00 for 10 consecutive business days.","If not compliant by Aug 12, may be eligible for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to cure via reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-024898","json":"https://secwatch.observer/filing/0001104659-24-024898.json","markdown":"https://secwatch.observer/filing/0001104659-24-024898.md","text":"https://secwatch.observer/filing/0001104659-24-024898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924024898/0001104659-24-024898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924024898/tm246424d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:10:11.080070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"967f430715a3d3078c4438eb21ce4c587e7b573d","claim":"SELLAS Life Sciences Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"February 14, 2024, SELLAS Life Sciences Group, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “SLS” at this time. In accordance with Nas","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924024898/0001104659-24-024898-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}